Sabra Health Care REIT, Inc. (SBRA) Q3 2025 Earnings Call Transcript
Sabra Health Care REIT, Inc. ( SBRA ) Q3 2025 Earnings Call November 6, 2025 1:00 PM EST Company Participants Lukas Hartwich - Executive Vice President of Finance Rick Matros - Chairman, President & CEO Talya Nevo-Hacohen - Executive VP, Chief Investment Officer & Treasurer Darrin Smith - Executive Vice President of Investments Michael Costa - Executive VP, CFO & Secretary Conference Call Participants Farrell Granath - BofA Securities, Research Division Austin Wurschmidt - KeyBanc Capital Markets Inc., Research Division William John Kilichowski - Wells Fargo Securities, LLC, Research Division Seth Bergey - Citigroup Inc., Research Division Juan Sanabria - BMO Capital Markets Equity Research Richard Anderson - Cantor Fitzgerald & Co., Research Division Alec Feygin - Robert W. Baird & Co. Incorporated, Research Division Michael Stroyeck - Green Street Advisors, LLC, Research Division Omotayo Okusanya - Deutsche Bank AG, Research Division Presentation Operator Good day, everyone.
Sabra (SBRA) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Sabra (SBRA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sabra Healthcare (SBRA) Meets Q3 FFO Estimates
Sabra Healthcare (SBRA) came out with quarterly funds from operations (FFO) of $0.38 per share, in line with the Zacks Consensus Estimate . This compares to FFO of $0.37 per share a year ago.
Sabra (SBRA) Upgraded to Buy: Here's Why
Sabra (SBRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sabra Health Care REIT, Inc. (SBRA) Q2 2025 Earnings Call Transcript
Sabra Health Care REIT, Inc. (NASDAQ:SBRA ) Q2 2025 Earnings Conference Call August 5, 2025 1:00 PM ET Company Participants Lukas Michael Hartwich - Executive Vice President of Finance Michael Lourenco Costa - Executive VP, CFO & Secretary Richard K. Matros - Chairman, President & CEO Talya Nevo-Hacohen - Executive VP, Chief Investment Officer & Treasurer Conference Call Participants Alec Gregory Feygin - Robert W.
Sabra (SBRA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Sabra (SBRA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sabra Healthcare (SBRA) Q2 FFO and Revenues Surpass Estimates
Sabra Healthcare (SBRA) came out with quarterly funds from operations (FFO) of $0.38 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to FFO of $0.36 per share a year ago.
Sabra Health: Steady Earnings, But Not Yet Fully Mature
SBRA is a solid healthcare REIT with stable revenues, moderate leverage, and, in my opinion, a defensive strategy focused on long-term profitability rather than aggressive market share growth. Despite a favorable supply-demand gap in senior care, SBRA's portfolio and income growth remain slow, with recent gains driven by rate increases and margin improvements. Dividend yield is attractive at 6.4%, but payout ratio is high and growth prospects are limited compared to sector peers with better diversification and lower risk exposure.
Sabra Health Care REIT: High Dividend And Growth Potential
With the market at all-time highs, I prefer durable, high-yield assets in real estate like Sabra Health Care REIT. SBRA has strong fundamentals, with a diversified healthcare portfolio, rising occupancy, robust tenant coverage, and a well-covered 6.5% dividend yield. Favorable demographics, limited new supply, and upcoming acquisitions support SBRA's growth outlook, with management guiding for double-digit NOI growth in senior housing.
Sabra Health Care REIT, Inc. (SBRA) Q1 2025 Earnings Call Transcript
Sabra Health Care REIT, Inc. (NASDAQ:SBRA ) Q1 2025 Results Conference Call May 6, 2025 1:00 PM ET Company Participants Lukas Hartwich - EVP, Finance Rick Matros - Chief Executive Officer, President & Chair Talya Nevo-Hacohen - CIO, Treasurer & EVP Michael Costa - Chief Financial Officer Conference Call Participants Elmer Chang - Scotiabank Farrell Granath - Bank of America Austin Wurschmidt - KeyBanc Capital Markets Juan Sanabria - BMO Capital Markets Seth Bergey - Citi George Dugan - Mizuho Securities Richard Anderson - Wedbush Alec Feygin - Baird Equity Research Operator Good day, everyone. My name is Kate, and I will be your conference operator today.
Sabra (SBRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Sabra (SBRA) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sabra Healthcare (SBRA) Q1 FFO and Revenues Surpass Estimates
Sabra Healthcare (SBRA) came out with quarterly funds from operations (FFO) of $0.37 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to FFO of $0.35 per share a year ago.
